339 related articles for article (PubMed ID: 26385374)
41. Blocking NF-κB sensitizes non-small cell lung cancer cells to histone deacetylase inhibitor induced extrinsic apoptosis through generation of reactive oxygen species.
Karthik S; Sankar R; Varunkumar K; Anusha C; Ravikumar V
Biomed Pharmacother; 2015 Feb; 69():337-44. PubMed ID: 25661379
[TBL] [Abstract][Full Text] [Related]
42. (S)-crizotinib induces apoptosis in human non-small cell lung cancer cells by activating ROS independent of MTH1.
Dai X; Guo G; Zou P; Cui R; Chen W; Chen X; Yin C; He W; Vinothkumar R; Yang F; Zhang X; Liang G
J Exp Clin Cancer Res; 2017 Sep; 36(1):120. PubMed ID: 28882182
[TBL] [Abstract][Full Text] [Related]
43. Panobinostat synergizes with bortezomib to induce endoplasmic reticulum stress and ubiquitinated protein accumulation in renal cancer cells.
Sato A; Asano T; Isono M; Ito K; Asano T
BMC Urol; 2014 Aug; 14():71. PubMed ID: 25176354
[TBL] [Abstract][Full Text] [Related]
44. Sensitivity of osteosarcoma cells to HDAC inhibitor AR-42 mediated apoptosis.
Murahari S; Jalkanen AL; Kulp SK; Chen CS; Modiano JF; London CA; Kisseberth WC
BMC Cancer; 2017 Jan; 17(1):67. PubMed ID: 28109246
[TBL] [Abstract][Full Text] [Related]
45. Antitumor effects of histone deacetylase inhibitor suberoylanilide hydroxamic acid in epidermal growth factor receptor-mutant non-small-cell lung cancer lines in vitro and in vivo.
Wei Y; Zhou F; Lin Z; Shi L; Huang A; Liu T; Yu D; Wu G
Anticancer Drugs; 2018 Mar; 29(3):262-270. PubMed ID: 29356692
[TBL] [Abstract][Full Text] [Related]
46. Anticancer effects of the MHY218 novel hydroxamic acid-derived histone deacetylase inhibitor in human ovarian cancer cells.
Jeon HS; Ahn MY; Park JH; Kim TH; Chun P; Kim WH; Kim J; Moon HR; Jung JH; Kim HS
Int J Oncol; 2010 Aug; 37(2):419-28. PubMed ID: 20596669
[TBL] [Abstract][Full Text] [Related]
47. Carfilzomib potentiates CUDC-101-induced apoptosis in anaplastic thyroid cancer.
Zhang L; Boufraqech M; Lake R; Kebebew E
Oncotarget; 2016 Mar; 7(13):16517-28. PubMed ID: 26934320
[TBL] [Abstract][Full Text] [Related]
48. The Therapeutic Potential of AN-7, a Novel Histone Deacetylase Inhibitor, for Treatment of Mycosis Fungoides/Sezary Syndrome Alone or with Doxorubicin.
Moyal L; Feldbaum N; Goldfeiz N; Rephaeli A; Nudelman A; Weitman M; Tarasenko N; Gorovitz B; Maron L; Yehezkel S; Amitay-Laish I; Lubin I; Hodak E
PLoS One; 2016; 11(1):e0146115. PubMed ID: 26752418
[TBL] [Abstract][Full Text] [Related]
49. The pan-HDAC inhibitor panobinostat acts as a sensitizer for erlotinib activity in EGFR-mutated and -wildtype non-small cell lung cancer cells.
Greve G; Schiffmann I; Pfeifer D; Pantic M; Schüler J; Lübbert M
BMC Cancer; 2015 Dec; 15():947. PubMed ID: 26675484
[TBL] [Abstract][Full Text] [Related]
50. A natural anthraquinone derivative shikonin synergizes with AZD9291 against wtEGFR NSCLC cells through reactive oxygen species-mediated endoplasmic reticulum stress.
Hu X; Zhang ZY; Wu LW; Zeng LH; Chen H; Zhu HJ; Zhang JK; Shao J; Zhang C; Li YL; Lin NM
Phytomedicine; 2020 Mar; 68():153189. PubMed ID: 32070867
[TBL] [Abstract][Full Text] [Related]
51. A novel histone deacetylase inhibitor exhibits antitumor activity via apoptosis induction, F-actin disruption and gene acetylation in lung cancer.
Tang YA; Wen WL; Chang JW; Wei TT; Tan YH; Salunke S; Chen CT; Chen CS; Wang YC
PLoS One; 2010 Sep; 5(9):e12417. PubMed ID: 20856855
[TBL] [Abstract][Full Text] [Related]
52. Oxidative and endoplasmic reticulum stress signaling are involved in dehydrocostuslactone-mediated apoptosis in human non-small cell lung cancer cells.
Hung JY; Hsu YL; Ni WC; Tsai YM; Yang CJ; Kuo PL; Huang MS
Lung Cancer; 2010 Jun; 68(3):355-65. PubMed ID: 19700217
[TBL] [Abstract][Full Text] [Related]
53. A novel combinatorial strategy using Seliciclib(®) and Belinostat(®) for eradication of non-small cell lung cancer via apoptosis induction and BID activation.
Ong PS; Wang L; Chia DM; Seah JY; Kong LR; Thuya WL; Chinnathambi A; Lau JY; Wong AL; Yong WP; Yang D; Ho PC; Sethi G; Goh BC
Cancer Lett; 2016 Oct; 381(1):49-57. PubMed ID: 27461583
[TBL] [Abstract][Full Text] [Related]
54. Potentiation of anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the cyclin-dependent kinase inhibitor P276-00 in human non-small-cell lung cancer cell lines.
Shirsath N; Rathos M; Chaudhari U; Sivaramakrishnan H; Joshi K
Lung Cancer; 2013 Nov; 82(2):214-21. PubMed ID: 24051085
[TBL] [Abstract][Full Text] [Related]
55. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer.
Shi YK; Li ZH; Han XQ; Yi JH; Wang ZH; Hou JL; Feng CR; Fang QH; Wang HH; Zhang PF; Wang FS; Shen J; Wang P
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1131-40. PubMed ID: 20838997
[TBL] [Abstract][Full Text] [Related]
56. Carfilzomib and oprozomib synergize with histone deacetylase inhibitors in head and neck squamous cell carcinoma models of acquired resistance to proteasome inhibitors.
Zang Y; Kirk CJ; Johnson DE
Cancer Biol Ther; 2014 Sep; 15(9):1142-52. PubMed ID: 24915039
[TBL] [Abstract][Full Text] [Related]
57. Antitumour activity of AMG 900 alone or in combination with histone deacetylase inhibitor SaHa on medulloblastoma cell lines.
Geron L; Borges KS; Andrade AF; Suazo VK; Scrideli CA; Tone LG
Neurol Res; 2015 Aug; 37(8):703-11. PubMed ID: 26000978
[TBL] [Abstract][Full Text] [Related]
58. Synergistic Combination of Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid and Natural Flavonoid Curcumin Exhibits Anticancer and Antibacterial Activity.
Altundağ EM; Toprak K; Şanlıtürk G; Güran M; Özbilenler C; Kerküklü NR; Yılmaz AM; Yalçın AS
Anticancer Agents Med Chem; 2021; 21(10):1301-1308. PubMed ID: 33023457
[TBL] [Abstract][Full Text] [Related]
59. Pax5 Re-expression in H460 Cells Treated with the Combination of Demethylating Agent and Histone Deacetylase Inhibitor is Associated with the Enhancement of P53 Binding to Pax5 Promoter Region.
Liang Y; Zeng J; Jelicks L; Ma S; Liu J; Mei J; Perez-Soler R; Zou Y
Curr Cancer Drug Targets; 2017; 17(2):169-176. PubMed ID: 27029827
[TBL] [Abstract][Full Text] [Related]
60. Induction of E-cadherin in lung cancer and interaction with growth suppression by histone deacetylase inhibition.
Kakihana M; Ohira T; Chan D; Webster RB; Kato H; Drabkin HA; Gemmill RM
J Thorac Oncol; 2009 Dec; 4(12):1455-65. PubMed ID: 20009910
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
